5results about How to "Enhanced lethality" patented technology

The invention relates to a nano antibody G11 for enhancing NK (Natural Killer) cells to kill tumor cells by utilizing ADCC (Adenosine Decarbonyl Cellulose) action and application of the nano antibody G11. The amino acid sequence of the antibody G11 comprises CDR1 shown as SEQ ID No.2, CDR2 shown as SEQ ID No.3 and CDR3 shown as SEQ ID No.4. The invention also relates to a preparation method of the nano antibody G11. The antibody and the CD147 protein have high affinity and specificity, and experiments prove that the antibody can effectively enhance the killing function of NK cells on cells expressing the CD147 protein through antibody-dependent cell-mediated cytotoxic action (ADCC).

The invention provides a tumor inhibition probiotic functional beverage based on an Xu5P enhancer and a preparation method of the tumor inhibition probiotic functional beverage, and relates to the technical field of biological medicines. Comprising the following raw materials in parts by weight: 10-20% of an Xu5P improver, 0.5-2.0% of a probiotic strain, 1-5% of an anti-tumor plant extract, 2-5% of functional cellulose, 0.1-1.0% of vitamins, 0.1-1.0% of a mineral additive, 0.1-2.0% of a polyphenol compound, 1-3% of a plant fermentation product, 0.5-3.0% of a plant-derived active compound, 1-3% of prebiotics, 1-3% of traditional Chinese medicine components and the balance of water. The Xu5P has no obvious influence on the migration and clone formation ability of tumor cells, but by applying the Xu5P or an accelerant thereof in a tumor mouse model, the metastasis of mouse tumors can be obviously reduced, and the CD8 + T cell infiltration and tumor killing function can be improved. The research finds that a scientific basis is provided for tumor treatment, especially tumor metastasis inhibition treatment.

The invention discloses a pharmaceutical composition for enhancing the killing power of CIK cells to tumor cells and application, and belongs to the technical field of biological medicine. The pharmaceutical composition is composed of a PD-1 monoclonal antibody and a protein phosphatase PP2A inhibitor, the PD-1 monoclonal antibody is Pembrolizumab, the protein phosphatase PP2A inhibitor is LB100, and the mass ratio of the PD-1 monoclonal antibody to the protein phosphatase PP2A inhibitor is (100-10): 1. Through combined use of the PD-1 monoclonal antibody and the protein phosphatase PP2A inhibitor LB100, by adjusting related signal channels in the CIK cells, immunosuppression of tumor cells on the CIK cells is relieved, the killing activity of the CIK cells on the tumor cells is remarkably improved, more powerful immune cell support is provided for tumor treatment, and good clinical application prospects are achieved.

The application discloses application of a retinoid analogue ZSH-512 in preparation of a liver cancer immunotherapy drug. Cell and animal model experiments show that the compound ZSH-512 can regulate an immune microenvironment of hepatocellular carcinoma, increase drug efficacy of an immune checkpoint inhibitor such as an anti-PD-1 antibody, and also improve anti-tumor efficacy of the ZSH-512 itself, so that a synergistic anti-tumor effect is achieved, the defect that liver cancer is not sensitive to single immunotherapy is overcome, and the ZSH-512 has a clinical development and application prospect.

The invention relates to an anti-CD147 single-domain antibody and application thereof. The amino acid sequence of the single-domain antibody comprises a CDR1 as shown in SEQ ID No. 2, a CDR2 as shown in SEQ ID No. 3 and a CDR3 as shown in SEQ ID No. 4. The single-domain antibody is strong in affinity, the chimeric antigen receptor T cell taking the single-domain antibody as an antigen binding domain is strong in tumor cell killing capability, and meanwhile, the antibody can enhance the tumor cell killing capability of NK cells through the ADCC effect.